Grifols (GIKLY) Equity Average (2011 - 2025)
Grifols (GIKLY) reported Equity Average of $6.2 billion for Q4 2025, down 13.55% on a YoY basis from $7.2 billion in Q4 2024, and down 13.55% quarter-over-quarter from $7.2 billion in Q4 2024.
Grifols (GIKLY) Equity Average (2011 - 2025) Analysis & Trends
Grifols has reported Equity Average for 12 years, with the latest figure at $6.2 billion in Q4 2025.
- For the quarter ending Q4 2025, Equity Average fell 13.55% year-over-year to $6.2 billion; the trailing twelve-month figure through Dec 2025 stood at $6.2 billion (down 13.55% YoY), and the FY2025 full-year result was $3.1 billion, up 9539.84% from the prior year.
- Equity Average for Q4 2025 stood at $6.2 billion, down from $7.2 billion in the prior quarter.
- The five-year high for Equity Average was $8.1 billion in Q4 2023, with the low at $3.7 billion in Q4 2021.
- Historically, Equity Average has averaged $6.6 billion across 5 years, with a median of $7.2 billion in 2024.
- Annual changes were most pronounced in 2022 — Equity Average surged 118.93% — and 2025, when it retreated 13.55%.
- Grifols' Equity Average stood at $3.7 billion in 2021, then surged by 118.93% to $8.0 billion in 2022, then increased by 1.49% to $8.1 billion in 2023, then slipped by 11.42% to $7.2 billion in 2024, then dropped by 13.55% to $6.2 billion in 2025.
- The last three Equity Average figures came in at $6.2 billion (Q4 2025), $7.2 billion (Q4 2024), and $8.1 billion (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 28.87 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 81.37 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | -4.96 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 49.27 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 8.92 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 23.11 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 88.29 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 19.27 Bn |
| 10 | Grifols | - | - | - | 6.21 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 6.21 Bn |
| Dec 31, 2024 | 7.19 Bn |
| Dec 31, 2023 | 8.11 Bn |
| Dec 31, 2022 | 7.99 Bn |
| Dec 31, 2021 | 3.65 Bn |
| Dec 31, 2017 | 4.11 Bn |
| Dec 31, 2016 | 3.98 Bn |
| Sep 30, 2016 | 3.89 Bn |
| Dec 31, 2015 | 3.59 Bn |
| Mar 31, 2015 | 3.43 Bn |
| Dec 31, 2014 | 2.88 Bn |
| Dec 31, 2013 | 2.52 Bn |
| Sep 30, 2013 | 2.49 Bn |
| Jun 30, 2013 | 2.48 Bn |
| Mar 31, 2013 | 2.44 Bn |
| Dec 31, 2012 | 2.29 Bn |
| Sep 30, 2012 | 2.33 Bn |
| Jun 30, 2012 | 2.30 Bn |
| Mar 31, 2012 | 2.22 Bn |
| Dec 31, 2011 | 2.25 Bn |